Ciphergen, Bio-Rad Sued Over SELDI Sale, Suit Alleges Violation of 2003 Settlement | GenomeWeb
Fresh from settling one lawsuit, Ciphergen Biosystems last week was hit with another alleging it is in breach of a licensing agreement with its former parent company.
 
The suit, filed last week in California Superior Court in Santa Clara by Molecular Analytical Systems, stems from Ciphergen’s sale in November of its surface enhanced laser desorption ionization platform to Bio-Rad Laboratories, which is also named as a defendant.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."